According to Coherent Market Insights, The Global Vaccines Market is estimated to be valued at USD 81.91 Billion in 2025 and is expected to reach USD 124.88 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.2% from 2025 to 2032. The global vaccines market is projected to experience steady growth over the forecast period, driven by expanding immunization initiatives from governments and private organizations aimed at reducing the prevalence of diseases such as influenza and measles.
Request Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/4914
Global Vaccines Market Key Takeaways
Global vaccine demand is likely to increase at a CAGR of 6.2% from 2025 to 2032.
Monovalent vaccines are projected to remain a highly sought-after type, accounting for nearly 3/5 of the global vaccines market share by 2025.
Based on technology, conjugate vaccines segment is expected to dominate the industry, capturing a 42.5% share of the global market in 2025.
By disease indication, pneumococcal disease category is slated to account for nearly one-third of the global vaccines industry share by 2025.
North America is set to retain its monopoly, capturing over 2/5 of the global market share by 2025.
Asia Pacific is poised to emerge as the most lucrative pocket for vaccine manufacturers, exhibiting the fastest growth rate.
Immediate Delivery Available | Buy This Premium Research Report: https://www.coherentmarketinsights.com/insight/buy-now/4914
Increasing Incidence of Infectious Diseases Spurring Market Growth
Coherent Market Insights’ latest vaccines market analysis outlines major factors driving industry growth. Increasing prevalence of infectious diseases is one such growth factor.
The global burden of infectious diseases like influenza, meningitis, hepatitis, HPV, and fever is increasing significantly. For instance,
On April 16, 2025, the Colombian government declared a national health emergency in response to a surge in yellow fever cases across the country.
On January 2025, the World Health Organization (WHO) reported outbreak of Ebola in Uganda.
This surge in infectious diseases and seasonal outbreaks is expected to drive demand for vaccines during the forecast period.
Vaccines have become highly sought-after healthcare products used for preventing and treating numerous diseases. They significantly enhance the immune system of individuals and thus provide longer protection against diseases.
According to the United Nations Children’s Fund (UNICEF), each year, vaccination saves 2 to 3 million children from deadly diseases. Rising need for protecting children from deadly chronic and infectious diseases like tuberculosis, dengue fever, influenza, and hepatitis will likely boost vaccines market growth.
Also Read: Preventive Vaccines Market Size, Share, Trends & Opportunities for 2025-2032
High R&D Costs and Lack of Storage Facilities Hampering Market Growth
The global vaccines market outlook looks promising due to rising prevalence of infectious diseases and increasing government initiatives. However, high R& D costs and lack of proper cold chain infrastructure may limit market growth to some extent during the forecast period.
Developing vaccines costs a lot because it needs high-tech equipment, long clinical trials, and government approvals. This makes it hard for smaller companies to enter the market, which slows down innovation and reduces competition.
In addition, many regions lack adequate temperature-controlled storage and transport infrastructure necessary for vaccines. This may also slow down overall vaccines market demand in the coming years.
Increasing Government Immunization Programs Unlocking Growth Opportunities
The looming threat of disease outbreaks is encouraging governments and international organizations like the WHO, Gavi, and UNICEF to expand immunization programs. For example, in June 2025, South Africa stepped up its vaccination campaign to fight a foot-and-mouth disease outbreak. These initiatives are expected to open revenue streams for manufacturers of vaccines.
Increasing regulatory support is expected to boost the vaccines market value in the coming years. Regulatory organizations like the FDA are increasingly approving new vaccines to combat chronic and infectious diseases.
The U.S. FDA, for instance, approved Sanofi’s MenQuadfi meningococcal vaccine for infants in May 2025. Similarly, in March 2025, FDA approved Freeze-dried version of Bavarian Nordic’s Mpox and Smallpox Vaccine.
Emerging Vaccines Market Trends
Rising interest in preventive healthcare is a key growth-shaping trend in the vaccine market. People, especially across developing and developed regions, are increasingly becoming aware of the benefits of immunization. This is encouraging them to opt for vaccines to prevent diseases, leading to increased market demand.
Advancements in vaccine technologies are paving way for the development of novel vaccines like mRNA vaccines, recombinant vaccines, and vector-based vaccines. Introduction and adoption of these advanced vaccines will likely boost market growth.
Leading vaccine manufacturers are increasing their spending in R&D to create cancer vaccines, multi-dose vaccines, and other types targeting rare diseases. This is likely to expand the product pipeline and strengthen competitive positioning, further driving growth in the vaccines market.
Also Read: Human Tuberculosis Vaccine Market Analysis and Forecast for 2025-2032
Analyst’s View
“The global vaccines industry is set to grow significantly, driven by rising prevalence of infectious diseases, increasing vaccination programs, and advancements in vaccine technologies,” said a senior analyst at CMI.
Current Events and Their Impact on the Vaccines Market
|
Event |
Description and Impact |
|
Monkeypox and Other Emerging Infectious Disease Responses |
|
|
EU Pharmaceutical Legislation Reforms |
o Impact: This is anticipated to streamline approval processes for vaccines. |
|
mRNA Platform Expansion |
|
Competitor Insights
Key companies in the vaccines market research report:
- Merck & Co., Inc.
- GlaxoSmithKline plc (GSK)
- Sanofi
- Pfizer Inc.
- Moderna, Inc.
- Johnson & Johnson
- AstraZeneca
- CSL Limited
- Novavax, Inc.
- BioNTech SE
- Emergent BioSolutions Inc.
- Takeda Pharmaceutical Company
- Valneva SE
- Bharat Biotech
- Sinovac Biotech Ltd.
- Serum Institute of India
- Sinopharm (China National Pharmaceutical Group)
- Vaxart, Inc.
- Vaccitech plc
- Inovio Pharmaceuticals, Inc.
Key Developments
In August 2025, Pfizer and BioNTech’s COMIRNATY monovalent COVID-19 vaccine was approved by the U.S. FDA for use in adults aged 65 and older, as well as individuals aged 5 to 64 with an increased risk of severe COVID-19.
In March 2025, Sanofi and Vietnam Vaccine JSV (VNVC) launched a new state-of-the-art vaccine manufacturing plant in Vietnam. The new facility is designed to produce and supply vaccines for domestic use and export.
In January 2025, The Oxford Vaccine Group launched a new clinical study, BiVISTA, to test an experimental vaccine designed to prevent enteric fever, a disease caused by Salmonella Typhi and Salmonella Paratyphi A bacteria.
In April 2024, Sanofi launched Verorab in the United Kingdom for both pre-exposure and post-exposure rabies prophylaxis. Verorab is an inactivated rabies vaccine designed to protect individuals against rabies.
Request For Customization: https://www.coherentmarketinsights.com/insight/request-customization/4914
Detailed Segmentation-
By Type Insights (Revenue, USD Bn, 2020 - 2032)
- Monovalent Vaccines
- Mulitvalent Vaccines
By Technology Insights (Revenue, USD Bn, 2020 - 2032)
- Conjugate Vaccines
- Recombinant Vaccines
- Inactivated and Subunit Vaccines
- Live Attenuated Vaccines
- Toxoid Vaccines
- Other Vaccine Technologies
By Dosage Form Insights (Revenue, USD Bn, 2020 - 2032)
- Tablets/Capsules
- Liquids
- Creams
- Gels
- Others
By Disease Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Pneumococcal Disease
- Influenza
- Combination Vaccines
- HPV
- Meningococcal Disease
- Herpes Zoster
- Rotavirus
- MMR
- Varicella
- Hepatitis
- DTP
- Polio
- RSV
- Other Disease Indications
By Route Of Administration: Insights (Revenue, USD Bn, 2020 - 2032)
- Intramuscular
- Subcutaneous
- Oral
- Intranasal
By Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Also Read: Vaccine Technologies Market Outlook for 2025-2032
Our Trusted Partners:
Worldwide Market Reports, Coherent MI, Stratagem Market Insights
Get Recent News:
https://www.coherentmarketinsights.com/news
About Us:
Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.
Contact Us:
Mr. Shah
Coherent Market Insights Pvt. Ltd,
U.S.: + 12524771362
U.K.: +442039578553
AUS: +61-8-7924-7805
INDIA: +91-848-285-0837
✉ Email: sales@coherentmarketinsights.com
